Vetixetine exerts an antidepressant effect mainly by increasing 5-HT concentrations in the central nervous system (CNS), has little effect on noradrenaline and dopaminergic neurons compared to other selective 5-HT reuptake inhibitors (SSRIS) or serotonin-noradrenaline reuptake inhibitors (SNRIS). Several clinical trials have shown that vortitaxine has better efficacy, safety and tolerance in the treatment of severe depression. Waroxetine is a potent serotonin reuptake inhibitor with high affinity for 5-HT transporters in humans and little affinity for noradrenaline transporters and dopamine transporters. Waroxetine is also a 5-HT 1 A receptor agonist, 5-HT 1 B receptor partial agonist, 5-HT 1 D, 5-HT 3 and 5-HT 7 receptor antagonist as well as a 5-HT uptake inhibitor. Waroxetine exerts antidepressant effects in rats by acting together on these receptors.